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to include an outpatient drug beneﬁt will decrease beneﬁciaries’
burden of multiple sclerosis. RESULTS: Few MS beneﬁciaries
(5%) reported that they did not get prescription medications that
were prescribed for them. Some beneﬁciaries (15%) reported
delaying health care due to the cost. The average out-of-pocket
cost of commonly used medications (e.g., baclofen (Baclofen®),
interferon beta-1B (Betaseron®), and ﬂuoxetine (Prozac®))
among the insured is about half the price borne by the under-
insured beneﬁciaries. For example, interferon beta-1B is $27 per
prescription among insured beneﬁciaries, and $58.50 among
under-insured beneﬁciaries. Similar results were found for other
medications that are common among MS beneﬁciaries. CON-
CLUSIONS: Our ﬁndings suggest that MS beneﬁciaries perceive
few economic barriers to necessary health care, particularly pre-
scription medications. However, we ﬁnd substantial differences
exist in the out-of-pocket price of commonly used medications
between under-insured and insured beneﬁciaries. These differ-
ences should attenuate with the expansion of Medicare to
include a drug beneﬁt decreasing the economic burden of multi-
ple sclerosis.
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OBJECTIVE: To develop a measure of treatment satisfaction
that assesses attributes speciﬁc to injected medications for mul-
tiple sclerosis (MS). METHODS: Item development for the MS
Treatment Satisfaction Questionnaire (MSTCQ) was initiated
with review of MS websites, literature, adverse effects, as well 
as interviews and focus groups with MS patients. Pilot testing
resulted in aggregation of items postulated to assess adverse
effects, difﬁculty of use, inconvenience, and discomforts. The
MSTCQ test instrument included nine items describing “Satis-
faction with the Injection System” and 11 items describing “Side
Effects.” The instrument was completed by 317 patients, ages
18–60 years, who had been using interferon-beta-1a subcuta-
neously for > six-months. RESULTS: The “Satisfaction with the
Injection System” subscale ﬁt a one-component solution with
internal consistency coefﬁcient with good cross-sectional relia-
bility (a = 0.70). A principal components analysis of the 11 items
assessing “Side Effects” resulted in a three-component solution:
ﬂu-like side effects (a = 0.82); injection-site reactions (a = 0.68),
and global items (a = 0.75). Test-retest reliabilities at one-week
(N = 55) were Satisfaction r = 0.68 (intraclass correlation coef-
ﬁcient); Side Effects: ﬂu-like side effects, r = 0.86; global evalu-
ation of side effects, r = 0.77; injection site side effects, r = 0.73.
Almost all correlations were statistically signiﬁcant (p < 0.001).
Correlations with demographic variables showed signiﬁcant
associations with the MSTCQ total and subscale scores. Age,
falling behind in work and home activities, and level of activ-
ity/independence exhibit the most consistent relationships to the
various MSTCQ measures. CONCLUSIONS: The initial devel-
opment and testing shows that the MSTCQ should provide
insight into the concerns of MS patients about their use of
injected medications. These data indicate that older respondents
and respondents who are relatively more active and independent
have a more favorable view of their MS treatment.
NEUROLOGICAL DISORDERS—Other
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OBJECTIVES: Restless Legs Syndrome (RLS) is a sensorimotor
disorder resulting in a desire to move the limbs, which often leads
to severe sleep disturbances. This study aims to compare the
health-related quality of life (HRQOL) burden that RLS places
on US and European (EU) individuals. METHODS: Analyzed
cross-sectional data (with screening, RLS symptom, and SF-36
items) from EU (France, N = 75; Germany, N = 25; Italy, N =
42; Spain, N = 37; UK, N = 44) and US (N = 158) samples. SF-
36 scores of persons with RLS were compared with patient (type-
2 diabetes, depression, osteoarthritis [OA]) and US general
population norms. Regression methods were applied to estimate
sociodemographically adjusted norm values and test for signiﬁ-
cance. Comparisons to norm were conducted: 1) maintaining the
case-mix of conditions that both RLS and general population
respondents presented (“total” burden); 2) statistically adjusting
for conditions not attributed to RLS (“unique” burden). Burden
is deﬁned as a negative deviation in SF-36 scores from norm asso-
ciated with the presence of a medical condition (e.g. RLS).
RESULTS: Relative to an average adult, total burden ranged
from 0.44 to 1.07 standard deviations (SD) below general pop-
ulation norm for US, and 0.49 to 1.04 SD for EU. Relative to
an average healthy adult, the unique burden ranged from 0.63
to 1.36 SD and from 0.91 to 1.48 SD below norm for both US
and EU samples, respectively, (where 0.5 SD is viewed as meeting
standards of minimal clinically important difference). US RLS
sufferers reported the greatest burden on physical domains; EU
on mental health. For both samples, RLS burden was greater
than type-2 diabetes and OA, and similar to depression. CON-
CLUSIONS: RLS places a sizable burden on HRQOL—similar
for US and EU samples, affecting both physical and mental
health. The EU sample is more affected in mental health; the US
sample is more affected in physical health.
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OBJECTIVES: Restless legs syndrome (RLS) is a sensorimotor
disorder characterized by an irresistible urge to move the limbs,
which often results in disturbed sleep. This study aims to con-
textualize the impact of RLS on health-related quality of life
(HRQOL) in terms of functional limitations, mental health and
resource use. METHODS: Cross-sectional data from an omnibus
questionnaire (with screening and RLS symptom items) and the
SF-36 Health Survey (to assess HRQOL) from a US sample of
158 participants with RLS were analyzed. Capitalizing on prior
work that linked external criteria to patients differing in general
health self-evaluations, we assessed SF-36 physical and mental
321Abstracts
component summary scores, the likely functional limitations,
mental health and health care utilization of patients with RLS.
RESULTS: RLS sufferers likely to currently be unable to work
due to their health were about three times that of US norm (22%
vs. 8%). About 22% of RLS sufferers were likely to lose their
job after one-year, compared with 3% norm. Moreover, RLS suf-
ferers at risk for diagnosis of clinical depression were over twice
that of US norm (40% vs. 18%). Additionally, they were also
more likely to report signiﬁcant stress than US norm (24% vs.
20%). Compared with US norm, RLS sufferers were more likely
to report limitations in daily activities, such as climbing several
ﬂights of stairs (71%) and lifting/carrying groceries (53%).
Finally, there were high rates of health care utilization for over
46% of RLS sufferers, compared with 13% for US norm. CON-
CLUSIONS: The sizable burden that RLS places on HRQOL is
associated with a likelihood of notably large functional limita-
tions, mental health stressors and health care resource use. There
is a signiﬁcant potential for RLS treatment to improve patients’
HRQOL and their associated functional and mental health, thus
potentially alleviating the impact on resource use.
NEUROLOGICAL DISORDERS—Parkinson’s Disease
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OBJECTIVES: To estimate the cost-effectiveness of dopamine
agonists such as pramipexole and piribedil on patients with early
Parkinson’s disease (PD). METHODS: Dopamine agonists have
been added to treatment of 40 early PD patients that received
amantadine and anticholinergics. A total of 18 patients (mean
age: 58.3 ± 7.7 years, mean duration of disease: 2.6 ± 1.1 years)
received pramipexole (mean dose: 2.4 ± 1.1mg) within one year
and 22 patients (mean age: 60.4 ± 5.6 years, mean duration of
disease: 3.2 ± 2.2 years) received piribedil (mean dose: 168.2 ±
24.6mg) within one year also. Clinical efﬁcacy was measured by
percentage reduction of Uniﬁed Parkinson Disease Rating Scale
(UPDRS). Only direct costs were estimated. Cost-effectiveness
ratio was deﬁned for both agonists. RESULTS: After one year 
of treatment by dopamine agonists, 40 early PD patients had
demonstrated signiﬁcant (p < 0.01) clinical improvement. Mean
percent UPDRS score reduction from basic treatment was 12.2%
in the pramipexole group of patients and 8.9% in the piribedil
group of patients. Patients had no adverse effects which could
lead to increase in cost of treatment. The mean cost for one-year
treatment of pramipexole was $1544.29 compared to $506.96
of piribedil. Cost-effectiveness ratio for pramipexole group was
$126.58 per 1% UPDRS score reduction, and $56.96 per 1%
UPDRS score reduction for the piribedil group. CONCLU-
SIONS: Treatment of early PD patients by dopamine agonists
such as pramipexol and piribedil resulted in signiﬁcant clinical
improvement. At the same time, use of piribedil is more cost-
effective than use of pramipexole for early PD patients.
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OBJECTIVES: To perform cost-utility analysis and calculated
Quality Adjusted Life Years (QALY) for dopamine agonists such
as Pramipexole and Piribedil on patients with early Parkinson’s
Disease (PD). METHODS: Basic treatment of 40 early PD
patients included amantadine and anticholinergics at least within
one year. Pramipexole (mean dose: 2.4 ± 1.1mg) was added to
basic treatment of 18 patients within one year, and Piribedil
(mean dose: 168.2 ± 24.6mg) was added to treatment of 22
patients within one year as well. To evaluate quality of life, we
included the 39-item Parkinson’s Disease Questionnaire (PDQ-
39) at baseline, one-year after basic treatment and one-year after
treatment by dopamine agonists. Utility was measured by per-
centage reduction of PDQ-39 and changes of summary index.
We carried out the cost-utility analysis and calculated QALY for
both agonists. Only direct costs were estimated. RESULTS:
Quality of life, characterized by summary index of PDQ-39,
changed compared with basic treatment from 0.516 (range 0–1)
up to 0.717 for Pramipexole group (mean percent PDQ-39 
score reduction was 20.1%). For the Piribedil group, summary
index of PDQ-39 changed compared with basic treatment from
0.618 up to 0.725 (mean percent PDQ-39 score reduction was
10.7%). For the Pramipexole group, mean cost of basic treat-
ment was $13.42 compared to $1544.29 of Pramipexole treat-
ment. For the Piribedil group, mean cost of basic treatment 
was $8.16 compared to $506.96 of Piribedil treatment. Cost-
utility for the Pramipexole group was $76.83 per 1% PDQ-39
score reduction and 47.38$ per 1% PDQ-39 score reduction 
for the Piribedil group. For early PD patients treated by
Pramipexole, QALY costs $1263.35 and $383.56 for patients
treated with Piribedil QALY. CONCLUSIONS: For early PD
patients, use of Piribedil is more cost-utility than use of
Pramipexole. QALY for Piribedil treatment costs much less than
Pramipexol treatment.
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OBJECTIVE: Parkinson’s Disease (PD) is a neurodegenerative
condition, with increasing resource use consequences as patients
progress. The purpose of this study was to investigate differences
in resource use for patients in different stages of PD.
METHODS: Data are drawn from a large cross-sectional obser-
vational study of patients receiving treatment for PD. A panel of
neurologists were asked to include the next ten patients con-
sulting with PD during a speciﬁed time period. Information col-
lected includes behavioural and attitudinal patient management
and resource use data. RESULTS: The study included 4234
patients treated by 428 doctors in the US and ﬁve European
countries. Disease state was measured by Hoehn and Yahr (HY)
scale, ranging from one (mild unilateral tremor, some rigidity,
minimal bradykinesia) to four (severe disability) and ﬁve (com-
plete immobility). Patients with HY score four and ﬁve were
grouped due to small numbers with HY ﬁve. There were no sig-
niﬁcant differences in HY distribution between the EU and US.
Likelihood of hospitalisation and admission for respite care is
much greater in Europe than the US (24.0% vs. 6.7%; p < 0.01
and 4.7% vs. 0.6%; p < 0.01). Hospital stay was also greater in
EU (16.3 vs. 6.7 days; p < 0.01). Likelihood of both hospitali-
sation and respite care correlated with worsening HY score.
Drug use patterns were similar in EU and US. Patients with HY
score of four and ﬁve took more drugs than patients with HY
one (mean number 2.15 vs. 1.15; p < 0.01). Likelihood of com-
bination therapy (particularly with levodopa) increased with
worsening HY score; at HY 4/5 levodopa therapy is much more
common than at HY1 (86% vs. 35%; p < 0.01). CONCLU-
